OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press72910.17650/1818-8346-2008-0-3-69-76СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯApproaches to treating anemia in patients with malignancies. The 2007—2008 changes in Russian and International practiceПодходы к лечению анемии у больных злокачественными новообразованиями. Изменения в российской и международной практике за 2007—2008 гг.ZhukovN. V.ЖуковН. В.
Russian Federation

Москва

Federal Research Clinical Centre of Pediatric Hematology, Oncology and Immunology, Russian Agency for Health CareФГУ ФНКЦ детской гематологии, онкологии и иммунологии Росздрава240820083697624112022241120222008https://oncohematology.abvpress.ru/ongm/article/view/729

The paper deals with the treatment policy, including erythropoiesis-stimulating drugs (ESD), in anemic patients with malignancies. The use of ESD remains the basic recommended treatment option for anemia in cancer patients treated with cytostatics if the causes of anemia, which are eliminable by other means, are absent. Introduction of darbepoetin α makes ESD therapy more convenient for patients and medical staff.

В статье рассматривается тактика лечения анемии у больных злокачественными новообразованиями, в частности, использование эритропоэзстимулирующих препаратов (ЭСП). Назначение ЭСП остается основным рекомендованным методом лечения анемии у онкологических больных, получающих терапию цитостатиками, при условии, что отсутствуют устранимые другим способом причины анемии. Внедрение в отечественную практику дарбэпоэтина α позволяет сделать терапию ЭСП более удобной для пациентов и медицинского персонала.

anemiaerythropoiesis-stimulating drugsdarbepoetin αанемияэритропоэзстимулирующие препаратыдарбэпоэтин α1. Ludwig H., Van Belle S., Barrett-Lee P. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40(15):2293—306.Ludwig H., Van Belle S., Barrett-Lee P. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40(15):2293—306.2. Groopman J.L., Itri L. Chemotherapy induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616—34.Groopman J.L., Itri L. Chemotherapy induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616—34.3. Bokemeyer C., Aapro M.S., Courdi A. et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40(15):2201—16.Bokemeyer C., Aapro M.S., Courdi A. et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40(15):2201—16.4. Rizzo J.D., Somerfield M.R., Hagerty K.L. et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. J Clin Oncol 2008;26:132—49.Rizzo J.D., Somerfield M.R., Hagerty K.L. et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. J Clin Oncol 2008;26:132—49.5. Rizzo J.D., Lichtin A.E., Woolf S.H. et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083—107.Rizzo J.D., Lichtin A.E., Woolf S.H. et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083—107.6. Bennett C.L., Silver S.M., Djulbegovic B. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299(8):914—24.Bennett C.L., Silver S.M., Djulbegovic B. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299(8):914—24.7. Crawford J., Cella D., Cleeland C.S. et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888—95.Crawford J., Cella D., Cleeland C.S. et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888—95.8. Vansteenkiste J., Pirker R., Massuti B. et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211—20.Vansteenkiste J., Pirker R., Massuti B. et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211—20.9. Vadhan-Raj S., Mirtsching B., Gregory S.A. et al. Baseline (BL) covariates of response to darbepoetin alfa (DA) every 2 weeks (Q2W) in patients (pts) with chemotherapy-induced anemia (CIA). Proc ASCO 2004;23:740.Vadhan-Raj S., Mirtsching B., Gregory S.A. et al. Baseline (BL) covariates of response to darbepoetin alfa (DA) every 2 weeks (Q2W) in patients (pts) with chemotherapy-induced anemia (CIA). Proc ASCO 2004;23:740.10. Canon J.-L., Vansteenkiste J., Bodoky G. et al. Randomized, doubleblind, active-controlled trial of every-3- week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273—84.Canon J.-L., Vansteenkiste J., Bodoky G. et al. Randomized, doubleblind, active-controlled trial of every-3- week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273—84.